Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases - Université de Lorraine Access content directly
Journal Articles The Lancet Gastroenterology & Hepatology Year : 2022

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

1 Hôpital Nord [CHU - APHM]
2 UMMSM - University of Miami Leonard M. Miller School of Medicine
3 University of Calgary
4 UC San Diego - University of California [San Diego]
5 UFPR - Universidade Federal do Parana [Curitiba]
6 UC San Francisco - University of California [San Francisco]
7 MSSM - Icahn School of Medicine at Mount Sinai [New York]
8 All India Institute of Medical Sciences [New Delhi]
9 AP-HP - Hopital Saint-Louis [AP-HP]
10 Massachusetts General Hospital [Boston]
11 SickKids - The Hospital for sick children [Toronto]
12 University of Toronto
13 Imperial College London
14 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
15 PUCPR - Pontifícia Universidade Católica do Paraná [Curitiba, Brasil] = Pontifical Catholic University of Paraná [Curitiba, Brazil] = Université catholique pontificale du Paraná [Curitiba, Brésil]
16 University Hospital of Heraklion
17 McGill University = Université McGill [Montréal, Canada]
18 Semmelweis University [Budapest]
19 Barts & The London School of Medicine and Dentistry
20 Hospital de São João [Porto]
21 Universidade do Porto = University of Porto
22 Evangelismos Athens General Hospital
23 CUHK - The Chinese University of Hong Kong [Hong Kong]
24 Trinity College Dublin
25 Clinic Barcelona Hospital Universitari
26 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
27 CIBERehd - Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas
28 IRCCS Ospedale San Raffaele [Milan, Italy]
29 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
30 Shanghai Jiao Tong University School of Medicine
31 University hospital of Zurich [Zurich]
32 The University of Chicago Medicine [Chicago]
33 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
34 Hospital Israelita Albert Einstein [São Paulo, Brazil]
35 Örebro University
36 Hôpital Cochin [AP-HP]
37 Goethe-Universität Frankfurt am Main
38 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
39 Service d'Hépato-gastro-entérologie [CHRU Nancy]
Curt Tysk
  • Function : Author

Abstract

Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic challenge. The aim of the Endpoints for Extraintestinal Manifestations in Inflammatory Bowel Disease Trials (EXTRA) initiative was to achieve international expert consensus on how to assess these manifestations in IBD trials. A systematic literature review was done to identify methods to diagnose extraintestinal manifestations in patients with IBD and measure treatment outcomes. A consensus meeting involving a panel of 41 attendees, including gastroenterologists and referral specialists, was held on March 31, 2021, as part of an International Organization for the Study of Inflammatory Bowel Diseases initiative. The panel agreed that a specialist's expertise is needed to confirm the diagnosis of extraintestinal manifestations before the inclusion of a patient in IBD trials, except for axial spondyloarthritis, for which typical symptoms and MRI can be sufficient. Easy-to-measure endpoints were identified to assess the response of extraintestinal manifestations to treatment without needing specialist involvement. For uveitis, peripheral spondyloarthritis, and arthralgia, endpoint measurements need specialist expertise. The timing of endpoint measurements was discussed for individual extraintestinal manifestations. The EXTRA consensus proposes guidelines on how to thoroughly evaluate extraintestinal manifestations within IBD trials, and recommends that these guidelines are implemented in future trials to enable prospective assessment of these manifestations and comparison between studies.

Dates and versions

hal-04165819 , version 1 (19-07-2023)

Identifiers

Cite

Lucas Guillo, Maria Abreu, Remo Panaccione, William Sandborn, Valderilio Azevedo, et al.. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology & Hepatology, 2022, 7 (3), pp.254-261. ⟨10.1016/S2468-1253(21)00297-1⟩. ⟨hal-04165819⟩
11 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More